1. PCSK9 Inhibitors and Cardiovascular Outcomes

2. PCSK9 Inhibitors

3. CV Outcomes Clinical Trial Data For PCSK9 Inhibitors

4. ODYSSEY OUTCOMES Primary Efficacy Endpoint

5. ODYSSEY OUTCOMES Efficacy Subgroup With Baseline LDL-C  100 mg/dL (Median Baseline LDL-C 118 mg/dL)

6. FOURIER Primary Efficacy Endpoint

7. 2013 ACC/AHA Guidelines to Manage Dyslipidemia

8. 2017 Updated ACC Consensus Document on Role of Nonstatin Therapies for LDL-C Lowering

9. Clinical Implications of PCSK9 Inhibitor Outcome Trials

10. Safety of PCSK9 Inhibitors

11. FOURIER and ODYSSEY OUTCOMES

12. Overall Results For PCSK9 Inhibitor Outcome Trials

13. ODYSSEY OUTCOMES vs FOURIER Patient Histories

14. ODYSSEY OUTCOMES vs FOURIER LLTs and Lipids

15. PCSK9 CVOTs Key Scientific Points

16. ODYSSEY OUTCOMES Secondary Efficacy Endpoints Hierarchical Testing

17. A Target Range for LDL-C

18. FOURIER Lower CV Event Rates With Lower LDL-C Levels, as Low as 20 mg/dL (~0.5 mmol/L)

19. PCSK9 Inhibitors in Clinical Care

20. Comparison of Lipid Guidelines by Society

21. Populations to Consider a PCSK9 Inhibitor

22. Personalizing Treatment

23. PRIMO Study Incidence of Muscle AEs

24. 2017 NLA Recommendations on the Use of PCSK9 Inhibitors

25. PCSK9 Inhibitors in Clinical Care

26. Patient Case

27. Patient Case Treatment Approach

28. Statin Intolerance

29. PCSK9 inhibitors in Patients with PAD

30. Abbreviations

31. Abbreviations (cont)